Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Real-World data shows mepolizumab may keep rare vasculitis in check Long-Term

NCT ID NCT07591753

Disease control Sponsor: European EGPA Study Group Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Sep 11, 2026 · Updated 2 times

Summary

This study followed 591 adults with eosinophilic granulomatosis with polyangiitis (EGPA) across Europe to see how well mepolizumab 300mg every 4 weeks works over the long term in everyday medical practice. Researchers looked at disease control, lung function, and safety by reviewing medical records. The goal is to understand if this dose helps patients stay well and reduce steroid use without unexpected side effects.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
mepolizumab (a biologic drug given as a shot every 4 weeks)
What this could lead to
If successful, this could confirm that mepolizumab 300mg/month is a safe and effective long-term treatment to control EGPA and reduce steroid use.
What could go wrong
This is an observational study, not a controlled trial, so results may be influenced by other factors. It also looks back at existing data, which can be less reliable than a prospective study.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

591 people

The number who actually took part.

Started

Sep 2025

Finished

Mar 2026

Lead sponsor

A research network

The lead sponsor is a research network or cooperative group.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Adult patients with eosinophilic granulomatosis with polyangiitis (EGPA) receiving mepolizumab 300 mg/4 weeks in routine clinical practice at participating European EGPA referral centers, either as the initial mepolizumab regimen or after dose escalation from 100 mg/4 weeks.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adult patients with eosinophilic granulomatosis with polyangiitis (EGPA). Patients who meet the 2022 American College of Rheumatology/European Alliance of Associations for Rheumatology (ACR/EULAR) Classification Criteria for EGPA or the criteria proposed in the MIRRA trial. * Patients receiving mepolizumab 300 mg/4 weeks, either as the first mepolizumab regimen or after dose escalation from mepolizumab 100 mg/4 weeks. * Availability of at least 3 months of follow-up data after mepolizumab initiation or after dose switch. * Written informed consent. Exclusion Criteria: \- Follow-up shorter than 3 months after mepolizumab initiation or after dose switch.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Eosinophilic granulomatosis with polyangiitis (Churg-Strauss) (EGPA) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

eosinophilic granulomatosis with polyangiitis vasculitis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Eosinophilic granulomatosis with polyangiitis (Churg-Strauss) (EGPA)

Contacts and locations

Locations

  • University of Florence

    Florence, Florence, 50134, Italy